Modified GRF 1-29
A synthetic analog of the first 29 amino acids of growth hormone-releasing hormone (GHRH) with four amino acid substitutions for enhanced stability, used to stimulate pulsatile growth hormone release from the pituitary gland.
Overview
Modified GRF 1-29 (also known as Mod GRF 1-29, tetrasubstituted GRF 1-29, or by its research designation CJC-1295 without DAC) is a synthetic peptide analog of the biologically active N-terminal 29-amino-acid fragment of human growth hormone-releasing hormone (GHRH). The native GHRH(1-29) sequence (sermorelin) retains full receptor-binding activity but is rapidly degraded in vivo by dipeptidyl peptidase IV (DPP-IV), which cleaves the Tyr1-Ala2 bond, yielding a plasma half-life of only 5–7 minutes. Modified GRF 1-29 addresses this limitation through four strategic amino acid substitutions — typically at positions 2 (D-Ala), 8 (Gln→Ala), 15 (Gly→Ala), and 27 (Met→Leu) — which confer resistance to DPP-IV cleavage and improve chemical stability, extending the effective half-life to approximately 30 minutes while maintaining full agonist activity at the GHRH receptor.
The mechanism of action of Modified GRF 1-29 involves binding to GHRH receptors on anterior pituitary somatotroph cells, activating the Gs-adenylyl cyclase-cAMP-PKA signaling cascade that triggers growth hormone (GH) synthesis and secretion. Importantly, this stimulation preserves the body's natural pulsatile GH release pattern and negative feedback regulation through IGF-1 and somatostatin, avoiding the supraphysiological, continuous GH elevation associated with exogenous recombinant GH administration. Clinical studies with GHRH analogs have demonstrated significant increases in GH pulse amplitude, circulating IGF-1 levels, lean body mass, and reductions in visceral adiposity. The related compound tesamorelin (Egrifta), which is also a modified GRF analog, received FDA approval in 2010 for the reduction of excess abdominal fat in HIV-associated lipodystrophy.
Modified GRF 1-29 is most commonly used in combination with growth hormone-releasing peptides (GHRPs) — ghrelin mimetics such as Ipamorelin, GHRP-2, or GHRP-6 — because GHRH and ghrelin act through complementary receptors to produce synergistic GH release far exceeding either stimulus alone. The standard research protocol involves subcutaneous injection of 100 mcg Modified GRF 1-29 combined with 100–200 mcg of a GHRP, administered 1–3 times daily (typically at bedtime to coincide with natural GH pulses, and optionally post-exercise and upon waking). This combination approach has become the foundation of peptide-based GH optimization protocols, preferred over direct GH administration for its physiological release pattern and lower risk profile. Side effects are generally mild and may include injection site reactions, facial flushing, headache, and transient water retention. Modified GRF 1-29 is distinct from CJC-1295 with DAC, which adds a Drug Affinity Complex to bind albumin and extend the half-life to 6–8 days, producing more continuous (rather than pulsatile) GH elevation.
Mechanism of Action
Structural Modifications
Modified GRF 1-29 retains the biologically active N-terminal 29 residues of native GHRH(1-44) with four strategic amino acid substitutions: Ala2 → D-Ala2 (DPP-IV resistance), Asn8 → Gln8 (asparagine rearrangement prevention), Ala15 → Ala15 (or Leu15), and Met27 → Leu27 or Nle27 (oxidation resistance). These modifications extend the effective half-life from approximately 5-7 minutes (native GHRH) to approximately 30 minutes while preserving full GHRHR binding affinity and efficacy.
GHRH Receptor Signaling Cascade
Modified GRF 1-29 binds the GHRH receptor (GHRHR), a class B G protein-coupled receptor expressed predominantly on anterior pituitary somatotrophs. Receptor activation couples to Gsα, stimulating adenylyl cyclase and elevating intracellular cAMP. cAMP activates protein kinase A (PKA), which phosphorylates CREB (cAMP response element-binding protein) at Ser133, driving transcription of the GH1 gene and Pit-1 expression. PKA also directly facilitates exocytosis of GH-containing secretory granules.
Pulsatile GH Release Pattern
Unlike continuous GH elevation (which downregulates GH receptor sensitivity), Modified GRF 1-29 preserves the physiological pulsatile GH secretion pattern. Administered during the trough between natural GH pulses or timed with endogenous GHRH release, it amplifies pulse amplitude without altering pulse frequency. This pulsatile pattern is critical for maintaining hepatic GH receptor sensitivity and optimal IGF-1 production via the JAK2/STAT5b pathway.
Synergy with GH Secretagogues
Modified GRF 1-29 produces synergistic GH release when combined with ghrelin mimetics (GHRP-6, GHRP-2, Ipamorelin, hexarelin). The GHRHR (cAMP/PKA) and GHS-R1a (PLC/PKC/Ca²⁺) pathways converge on somatotroph calcium mobilization and vesicle exocytosis, producing GH release that is 5-10 fold greater than either pathway alone. This mirrors the physiological synergy between hypothalamic GHRH and ghrelin.
Feedback Regulation
GH and IGF-1 produced in response to Modified GRF 1-29 activate negative feedback at multiple levels: hypothalamic somatostatin release is increased, GHRH neuron activity is suppressed, and pituitary GHS-R1a expression is modulated. This built-in feedback prevents excessive GH elevation and maintains physiological regulation, distinguishing Modified GRF 1-29 from exogenous GH administration which bypasses these controls.
Reconstitution Calculator
Research
Reported Effects
Timing Critical:: Most effective when administered before sleep or during natural GH secretion windows, with benefits diminishing due to rapid clearance. Somatostatin Interaction:: Effectiveness is significantly influenced by somatostatin tone, with better results when somatostatin activity is reduced through natural circadian patterns or other interventions. Desensitization Risk:: Research suggests potential for reduced responsiveness with repeated bolus injections in short timeframes, though chronic use patterns show maintained effects in some studies. Synergistic Potential:: May work more effectively when combined with substances that reduce somatostatin or enhance cholinergic activity, based on neuroendocrine pathway studies
- Most effective when administered before sleep or during natural GH secretion windows, with benefits diminishing due to rapid clearance
- Effectiveness is significantly influenced by somatostatin tone, with better results when somatostatin activity is reduced through natural circadian patterns or other interventions
- Research suggests potential for reduced responsiveness with repeated bolus injections in short timeframes, though chronic use patterns show maintained effects in some studies
- May work more effectively when combined with substances that reduce somatostatin or enhance cholinergic activity, based on neuroendocrine pathway studies
GHRH analogue pharmacology
Modified GRF 1-29 (also called CJC-1295 without DAC or 'Mod GRF 1-29') is a tetrasubstituted analogue of the first 29 amino acids of growth hormone-releasing hormone. Amino-acid substitutions (e.g., D-Ala, Gln, Ala, Leu) protect it from dipeptidyl peptidase-IV and trypsin cleavage, extending its half-life relative to native GHRH/sermorelin while preserving GHRH-receptor agonism and physiologic, pulsatile GH release from the pituitary.
- Protease-resistant GHRH(1-29) analogue with GHRH-receptor agonism
- Stimulates pulsatile, physiologic GH secretion rather than exogenous GH
- Short-acting (minutes to hours) because it lacks the DAC albumin-binding linker
Relationship to CJC-1295 (with DAC)
The only published human clinical pharmacology comes from CJC-1295 with DAC, in which a drug-affinity-complex maleimide linker binds serum albumin to extend the half-life to roughly a week, producing sustained multi-day GH/IGF-1 elevation. Mod GRF 1-29 shares the same modified GHRH core but omits the DAC linker, so it acts as a short pulse; this distinction is central because the multi-day pharmacodynamics documented for CJC-1295 do not transfer to the no-DAC peptide.
- CJC-1295 with DAC: albumin-binding, ~1-week half-life, sustained GH/IGF-1 rise
- Mod GRF 1-29 (no DAC): brief GH pulse, favored for more physiologic dosing
- No dedicated controlled trials of the no-DAC form
Combination use with ghrelin secretagogues
In research and off-label practice, Mod GRF 1-29 is frequently combined with a selective ghrelin-receptor agonist such as ipamorelin, on the rationale that stimulating GH release through two distinct receptors (GHRH receptor plus ghrelin/GHS-R) produces greater, more synergistic GH output than either alone. This combination has not been formally evaluated in controlled human trials.
- Dual-pathway GH stimulation rationale (GHRH-R + ghrelin-R)
- Commonly paired with ipamorelin in compounded protocols
- Combination efficacy/safety not established in trials
Safety Profile
Side effects are typically mild and transient, including injection site flushing, warmth, and dizziness. It should be used with caution in individuals with active cancer or diabetic retinopathy. Long-term safety is not fully established, and it should be avoided during pregnancy and breastfeeding.
Pharmacokinetic Profile
Research Indications
Growth Hormone Axis (research / off-label)
Modified GRF 1-29 (CJC-1295 without DAC) is a stabilized GHRH(1-29) analogue used off-label/research to stimulate pulsatile endogenous GH release, often paired with a ghrelin-receptor secretagogue (e.g., ipamorelin).
Used off-label in the belief that increased GH/IGF-1 supports lean mass, fat loss and recovery; no controlled trials of the no-DAC peptide support these claims.
Related Compound Data (CJC-1295 with DAC)
The DAC-conjugated long-acting form (CJC-1295 with DAC) produced sustained multi-day GH/IGF-1 increases in Phase 1 studies; Mod GRF 1-29 lacks DAC and acts over minutes to hours.
Safety Profile
Common Side Effects
- Histamine Release:: Research demonstrates potential for histamine release from mast cells through Gi-protein activation, which could cause allergic-type reactions in sensitive individuals
- Receptor Cross-reactivity:: Studies show interaction with VIP receptors beyond GHRH receptors, potentially causing broader physiological effects than anticipated
- Quality Concerns:: Users report issues with peptides not fully dissolving upon reconstitution, raising questions about product purity and effectiveness
- Desensitization Effects:: Repeated administration in short intervals may reduce responsiveness, suggesting the importance of proper dosing schedules
References (9)
- [5]Effects of active immunization against somatostatin on serum growth hormone concentration in growing pigs
→ Immunization against somatostatin enhanced both basal GH levels and GH response to GRF administration, demonstrating that reducing somatostatin tone potentiates GRF effectiveness and prevents desensitization to repeated GRF injections.
- [7]Studies on alpha 2-adrenergic modulation of hypothalamic somatostatin secretion in rats
→ Alpha-2 adrenergic stimulation enhanced GH responsiveness to GRF only when somatostatin release was elevated, indicating that central adrenergic pathways primarily exert inhibitory effects on hypothalamic somatostatin secretion.
- [1]Interaction of growth hormone-releasing factor (GRF) and 14 GRF analogs with vasoactive intestinal peptide (VIP) receptors of rat pancreas
→ This study characterized how GRF 1-29 and its analogs interact with VIP receptors and identified specific structural modifications that affect receptor binding affinity and adenylate cyclase activation, showing that alterations in certain amino acid positions significantly impact biological activity.
- [2]Influence of dopaminergic, adrenergic and cholinergic blockade and TRH administration on GH responses to GRF 1-29
→ Research demonstrated that cholinergic pathways significantly influence GH response to GRF 1-29, while dopaminergic and alpha-adrenergic blockade showed no effect, suggesting neurotransmitter control may be exerted at both hypothalamic and pituitary levels.
- [3]Study of the activation mechanism of human GRF(1-29)NH2 on rat mast cell histamine release
→ GRF 1-29 was found to release histamine from mast cells through a non-cytotoxic mechanism involving Gi-protein activation and calcium uptake, with protein kinase C playing an amplifying role in the response.
- [4]Effects of a chronic GRF treatment on lambs having low or normal birth weight
→ Long-term GRF treatment (45-90 days) induced greater and more prolonged GH release in low birthweight lambs compared to normal birthweight animals, suggesting differential responsiveness based on physiological status.
- [6]Clonidine pretreatment modifies the growth hormone secretory pattern induced by short-term continuous GRF infusion in normal man
→ A 10-hour continuous GRF infusion study showed that alpha-2 adrenergic stimulation with clonidine modulated GH secretion patterns, with effects varying based on baseline somatostatin tone, suggesting complex neuroendocrine interactions.
- [8]Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults Journal of Clinical Endocrinology & Metabolism (2006)
→ In healthy adults, single subcutaneous doses of the DAC-conjugated long-acting analog CJC-1295 raised mean GH 2-10 fold for 6+ days and IGF-1 1.5-3 fold for 9-11 days (half-life ~5.8-8.1 days), with no serious adverse effects; Mod GRF 1-29 is the same core sequence without the DAC linker, so it shares the receptor mechanism but a much shorter duration.
- [9]Prakash A, Goa KL Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency BioDrugs (1999)
→ Sermorelin, GHRH(1-29), is the shortest fully active GHRH fragment and stimulates physiologic pituitary GH secretion; Mod GRF 1-29 is a tetrasubstituted, protease-resistant version of this same GHRH(1-29) sequence.
Mod GRF / Ipamorelin / GHRP-2 Blend
This triple-peptide blend combines Mod GRF 1-29 (Modified Growth Hormone Releasing Factor), a tetrasubstituted GHRH analogue with improved metabolic stability,
Motilin
Motilin is a 22-amino-acid linear peptide hormone secreted by specialized enteroendocrine cells (Mo cells) in the mucosal epithelium of the duodenum and proxima